17. Tan is В. C., van den Bosch M. A., Kemmeren J. M. Oral contraceptives and the risk of myocardial infarction. N. Engl. J. Med. 2001; 345: 1787-1793.
18. Ventura S., Mosher W., Curtin S. et al. Trends in pregnancy rates for the United States, 1976-97: an update. Nat. Vital Stat. Rep. 2001; 49: 1-10.
19. Bellamy L. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br. Med. J. 2007; 335: 974-985.
20. Beiaen В., Geerinckx K., Vergauwe P. Internal jugular vein thrombosis after ovarian stimulation. Hum. Reprod. 2001; 16: 510-512.
21. Akdemir R., Uyan C., Emiroglu Y. Acute myocardial infarction secondary thrombosis associated with ovarial hyperstimulation syndrome. Int. J. Cardiol. 2002; 83 (2): 187—189.
22. Eiford K., Leader A., Wee R., Stys P. K. Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intraarterial rt-PA. Neurology 2002; 59 (8): 1270-1272.
23. Palmer С. M. Incidence of electrocardiographic changes during cesarean delivery under regional anesthesia. Anesth. Analg. 1990; 70: 36-43.
24. Leiserowitz G., Evans A., Samuels S. Creatine kinase and its MB isoenzyme in the third trimester and the peripartum period. J. Reprod. Med. 1992; 37: 910-916.
25. Shivers S., Wians S., Keffer H,, Ramin S. Maternal cardiac troponin I levels during normal labor and delivery. Am. J. Obstetr. Gynecol. 1999; 180: 122-127.
26. Bell D., Nappy J. Myocardial infarction in women: A critical appraisal of gender differences in outcomes. Pharmacotherapy. 2000; 20 (9): 1034-1044.
27. Sattar N., Greer L. A. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? Br. Med. J. 2002; 325: 157-160.
28.Основные показатели деятельности акушерско-гинекологической службы Российской Федерации в разрезе федеральных округов (стат. материалы). М.; 2007.
29. Reimold S. С., Rutherford J. D. Valvular heart disease in pregnancy. N. Engl. J. Med. 2003; 349: 52-59.
30.ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J. Am. Coll. Cardiol. 1998; 32: 1486- 1588.
31. Maqueda I. G., Romero E. A., Recasens J. D. Guias de practica clinica de la Sociedad Espanola de Cardiologia en la geslante con cardiopatia. Rev. Esp. Cardiol. 2000; 53: 1474-1495.
32. Кулешова А. Г. Исходы беременности при различных гемодинамических группах врожденных пороков сердца. Патол. кровообращ. и кардиохир. 2001; 2: 12—18.
33. Приказ Минздравсоцразвития № 736 от 05.12.07 "Перечень медицинских" показаний к прерыванию беременности". М.; 2007.
34. Макацария А. Д., Беленков Ю. Н., Вейман А. П. (ред.). Беременность и врожденные пороки сердца. М.: Руссо; 2001.
35.Abdel-Hady Е. S., El-Shamy М., El-Rifai A. A. Maternal and perinatal outcome of pregnancies complicated by cardiac disease. Int. J. Gynaecol. Obstetr. 2005; 90: 21—25.
36. Khairy P., Ouyang D. W., Fernandes S. M. et al. Pregnancy outcomes in women with congenital heart disease. Circulation. 2006; 113: 517-524.
37. Breuer H. W. Auscultation of the heart in pregnancy Munch. Med. Wschr. 1981; 123: 1705-1707.
38. Арболишвили Г. H., Мареев В. И., Орлова Л. А., Беленков И. Н. Вариабельность сердечного ритма при хронической сердечной недостаточности и ее роль в прогнозе заболевания. Кардиология 2006; 46 (12): 4—11.
39. Глотова О. В. Оптимизация акушерской тактики у больных с митральным пороком сердца: Автореф. дис.... канд. мед. наук. 2005.
40. Frankenstein L., Nelles М., Slavutsky М. et al. Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J. Heart Lung Transplant. 2007; 26: 1033-1039.
41. Kimura K., Ieda M., Kanazawa H. et al. Cardiac sympathetic rejuvenation: a link between nerve function and cardiac hypertrophy. Circ. Res. 2007; 100: 1755-1764.
42. Kiriazis H., Du X. J., Feng X. et al. Preserved left ventricular structure and function in mice with cardiac sympathetic hyper- innervation. Am. J. Physiol. 2005; 289: H1359-H1365.
43. Freed L. A., Stein К. M., Borer J. S. et al. Relation of ultra-low frequency heart rate variability to the clinical course of chronic aortic regurgitation. Am. J. Cardiol. 1997; 79: 1482—1487.
44. Blase A., Carabello B. The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease, J. Heart Valv. Dis., 1995; 4 (suppl. II): 132— 139.
45. Yamada Y, Okumura K., Hashimoto H. et al. Altered myocardial acetylcholine and norepinephrine concentrations in right ventricular hypertrophy and failure. Heart Vessels, 1991; 6: 150-157.
46. Lindpaintner K, Lund D. D., Schmid P. O. Effects of chronic progressive myocardial hypertrophy on indexes of cardiac autonomic innervation. Circ. Res. 1987; 61: 55—62.